• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Elevated Aminotransferase Levels and Intracerebral Hemorrhage Deaths in a General Japanese Population
Int Heart J. 2023;64(4):678-683. doi: 10.1536/ihj.23-027.ABSTRACTAlthough chronic liver disease has been associated with cardiovascular disease, to which metabolic syndrome might be related, intracerebral hemorrhage (ICH) generally has not been focused. Associations of chronic liver disease assessed by aspartate (AST) and alanine (ALT) aminotransferase levels with ICH deaths were examined using 15,952 subjects without a history of cardiovascular disease who underwent annual health checkups in 1997 in Japan. Proportional hazards regression analyses adjusted for age, sex, hypertension, current smoking, diabetes mellitus, dri...
Source: International Heart Journal - July 30, 2023 Category: Cardiology Authors: Hisako Tsuji Ichiro Shiojima Source Type: research

E-040 Natural history of vertebrobasilar dolichoectasia - multinational study
ConclusionThis study verifies malignancy of VBADA and encourage invasive treatment in early phase of disease progression based on radiological characteristics, age and sex of the patients when treatment option is seen suitable.Disclosures B. Rezai Jahromi: None. N. Ota: None. V. Srinivasan: None. S. Henriksson: None. R. Dashti: None. C. Schwartz: None. J. Jääskeläinen: None. A. Lindgren: None. T. Koivisto: None. B. Jahromi: None. K. Noda: None. M. Potts: None. R. Tanikawa: None. Y. Kalani: None. P. Vajkoczy: None. R. Spetzler: None. F. Göhre: None. J. Hernesniemi: None. M. Lawton: None. M. N...
Source: Journal of NeuroInterventional Surgery - July 30, 2023 Category: Neurosurgery Authors: Rezai Jahromi, B., Ota, N., Srinivasan, V., Henriksson, S., Dashti, R., Schwartz, C., Jääskeläinen, J., Lindgren, A., Koivisto, T., Jahromi, B., Noda, K., Potts, M., Tanikawa, R., Kalani, Y., Vajkoczy, P., Spetzler, R., Göh Tags: SNIS 20th annual meeting electronic poster abstracts Source Type: research

Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
Partnership combines Roche ’s proven track record of successfully developing and launching innovative medicines worldwide withAlnylam ’s leadership in RNAi therapeuticsZilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressureHypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.1Basel, 24 July 2023 - Roche (SIX: RO, ROG; OT...
Source: Roche Media News - July 24, 2023 Category: Pharmaceuticals Source Type: news

Risk and population attributable fraction of stroke subtypes in Japan
CONCLUSION: Although there are differences according to the subtypes, hypertension could be regarded as the most crucial target for preventing strokes in Japan.PMID:37460296 | DOI:10.2188/jea.JE20220364
Source: Journal of Epidemiology - July 17, 2023 Category: Epidemiology Authors: Hiroshi Yatsuya Kazumasa Yamagishi Yuanying Li Isao Saito Yoshihiro Kokubo Isao Muraki Manami Inoue Shoichiro Tsugane Hiroyasu Iso Norie Sawada Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20